ENTA : Summary for Enanta Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 1 hr 3 mins

Enanta Pharmaceuticals, Inc. (ENTA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.76-0.21 (-0.75%)
As of 2:54PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close27.97
Bid27.77 x 100
Ask27.82 x 200
Day's Range27.65 - 28.08
52 Week Range20.79 - 37.31
Avg. Volume238,450
Market Cap528.59M
PE Ratio (TTM)-55.52
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017
    Capital Cube9 days ago

    Enanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q1, 2017 By the Numbers : February 15, 2017

    Categories: Yahoo Finance Get free summary analysis Enanta Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Enanta Pharmaceuticals, Inc. – Vertex Pharmaceuticals Incorporated, AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Novartis AG Sponsored ADR (VRTX-US, ABBV-US, MRK-US, JNJ-US, ... Read more (Read more...)

  • Associated Press16 days ago

    Enanta Pharmaceuticals reports 1Q loss

    On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 26 cents. The biotechnology company posted revenue of $10.4 million in the period. Enanta Pharmaceuticals shares have ...

  • Business Wire16 days ago

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016

    Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2016.